美第奇新星生物技術 MNOV 深 滬
等待開盤 09-12 09:30:00 美东时间
1.25
-0.020
-1.57%
華盛通- 最 高1.29
- 今 開1.29
- 成交量 2.04万股
- 最 低 1.25
- 昨 收 1.27
- 總市值 6130.78万
- 52周最高 2.55
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 1.13
- 委 比 95.59%
- 總股本 4904.62万
- 歷史最高 14.50
- 量 比 0.66
- 振 幅 3.15%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CMS Sets Preliminary Payment for Immunovia’s PancreaSure Test
Immunovia AB ( ($SE:IMMNOV) ) just unveiled an update. Immunovia announced that...
09-11 14:37
MediciNova Issues Shareholder Update; Secures $30M SEPA To Advance R&D As COMBAT-ALS Trial Hits Enrollment Target; NIH-Funded EAP And MN-001 Diabetes Study Near Completion
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), provides a shareholder
09-08 21:12
MediciNova Provides Shareholder Update on Key Developments
MediciNova signed a $30 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, completing patient enrollment in its COMBAT-ALS trial for ALS treatment MN-166, which showed encouraging results. The company also advances MN-001 trials for hypertriglyceridemia and fatty liver disease. CEO emphasizes flexibility in accessing capital and future updates.
09-08 13:00
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediciNova, Inc., a biopharmaceutical company, announced that its President and CEO, Dr. Yuichi Iwaki, and Chief Business Officer, Dr. David H. Crean, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, held from September 8-10, 2025, at the Lotte New York Palace Hotel. The presentation will be available on-demand starting September 5, 2025, at 7:00am ET via a webcast on the company's investor relati...
09-03 11:00
Immunovia Launches PancreaSure Test for Early Pancreatic Cancer Detection
Immunovia AB ( ($SE:IMMNOV) ) has provided an update. Immunovia AB has launched...
09-02 15:32
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MediciNova, Inc. announces successful enrollment of target participants in its COMBAT-ALS Phase 2b/3 clinical trial for MN-166 (ibudilast) to treat Amyotrophic Lateral Sclerosis (ALS). MN-166 is also in development for other neurodegenerative diseases, including progressive MS, DCM, Long COVID, and substance use disorder. The company highlights this milestone as a significant step forward, thanking all participants and contributors.
08-26 23:00
MediciNova Q2 EPS $(0.07) Beats $(0.10) Estimate, Sales $134.599K
MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 26.32 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same
08-15 05:57
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
MediciNova, Inc. has entered into a $30 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP. Under the agreement, MediciNova can sell its common stock over 36 months at 97% of the market price to finance R&D and corporate activities. The company's President and CEO, Dr. Yuichi Iwaki, emphasized the flexibility and strategic benefits of this arrangement for advancing their programs and capitalizing on market conditio...
07-31 23:30
Immunovia’s PancreaSure Test Gains Prestigious Recognition
Immunovia AB ( ($SE:IMMNOV) ) has issued an announcement. Immunovia AB’s analyt...
07-28 15:32
